SIGA Technologies to Host Business Update Call on May 6th, 2021 Following Release of First Quarter 2021 Financial Results
SIGA Technologies, Inc. (SIGA) announced a webcast and conference call scheduled for May 6, 2021, at 4:30 P.M. ET to provide a business update. CEO Phil Gomez and CFO Daniel Luckshire will participate. SIGA specializes in health security, primarily focusing on countermeasures against biological threats. Its lead product, TPOXX®, is a treatment for smallpox, with the US holding a stockpile of 1.7 million treatment courses. The company signed a potentially $600 million contract with BARDA in 2018 for TPOXX® development and procurement.
- SIGA maintains a strategic stockpile of 1.7 million TPOXX® treatment courses in the US.
- Signed a potentially $600 million contract with BARDA for TPOXX® development and procurement.
- None.
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 6, 2021. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer and Daniel Luckshire, Chief Financial Officer.
A live webcast of the call will also be available on the Company's website at www.siga.com under the 'Events & Presentations' tab in the Investor Relations section, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
Participants may access the call by dialing 1-800-891-3448 for domestic callers or 1-416-641-6700 for international callers.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 21993669. The archived webcast will be available in the Events and Presentations section of the Company's website.
ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX® is a novel small-molecule drug and the US maintains a stockpile of 1.7 million courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX® was approved by the FDA for the treatment of smallpox in 2018. The full label is here: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce826ab-4d6a-4139-a2ee-a304a913a253. In September 2018, SIGA signed a contract potentially worth more than
About Smallpoxi
Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.
FORWARD-LOOKING STATEMENTS
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the year ended December 31, 2020, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.
The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.
Investor Contacts:
Laine Yonker, Edison Group
lyonker@edisongroup.com
Michael Crawford, Edison Group
mcrawford@edisongroup.com
____________________
i http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
FAQ
What is the purpose of SIGA's conference call on May 6, 2021?
Who will participate in SIGA's May 6, 2021, conference call?
What is TPOXX® and its significance for SIGA Technologies?
How much did SIGA potentially contract with BARDA for TPOXX®?
